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SUMMARY
Sequential multiple assignment randomized trials (SMART) are used to develop optimal treat-
ment strategies for patients based on their medical histories in different branches of medical and
behavioral sciences where a sequence of treatments are given to the patients; such sequential
treatment strategies are often called dynamic treatment regimes. In the existing literature, the
majority of the analysis methodologies for SMART studies assume a continuous primary out-
come. However, ordinal outcomes are also quite common in medical practice; for example, the
quality of life (poor, moderate, good) is an ordinal variable. In this work, first, we develop the
notion of dynamic generalized odds-ratio (dGOR) to compare two dynamic treatment regimes
embedded in a 2-stage SMART with an ordinal outcome. We propose a likelihood-based ap-
proach to estimate dGOR from SMART data. Next, we discuss some results related to dGOR
and derive the asymptotic properties of it’s estimate. We derive the required sample size formula.
Then, we extend the proposed methodology to aK-stage SMART. Finally, we discuss some alter-
native ways to estimate dGOR using concordant-discordant pairs and multi-sample U -statistic.
A simulation study shows the performance of the estimated dGOR in terms of the estimated
power corresponding to the derived sample size. We analyze data from STAR*D, a multistage
randomized clinical trial for treating major depression, to illustrate the proposed methodology. A
freely available online tool using R statistical software is provided to make the proposed method
accessible to other researchers and practitioners.
Some key words: Generalized odds-ratio, distinct-path, shared-path, embedded regimes, STAR*D, sample size,
response-rate.
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1. INTRODUCTION
Personalized medicine is an increasingly important theme in biomedical research. Dynamic
treatment regimes (DTRs) (Murphy, 2003; Robins, 2004) offer a vehicle to operationalize per-
sonalized medicine in time-varying treatment settings; they are often used in the management of
chronic conditions where a patient is typically treated at multiple stages, e.g., alcohol and drug
abuse (Lei et al., 2012), tobacco addiction (Chakraborty et al., 2010), chronic types of cancer
(Thall et al., 2007; Zhao et al., 2011; Wang et al., 2012), HIV infection (Robins et al., 2008), and
mental illnesses (Dawson & Lavori, 2004; Shortreed & Moodie, 2012; Chakraborty et al., 2013;
Laber & Zhao, 2015; Song et al., 2015). Precisely, DTRs are decision rules that recommend se-
quences of treatments based on an individual patient’s evolving treatment and covariate history.
Once constructed based on data, these rules can be employed to give treatments to the patients
to optimize the outcome, depending on the individual patient’s medical history.
Sequential Multiple Assignment Randomized Trial (SMART) (Lavori & Dawson, 2000, 2004;
Thall et al., 2000; Murphy, 2005) is a special kind of clinical trial that provides high-quality data
for comparing or constructing DTRs; the data from such trials are less vulnerable to causal con-
founding than longitudinal observational data. Methodological research on SMARTs has been
on the rise in recent years, in accordance with the increasing prevalence of SMART or similar
designs in practice, e.g., in cancer (Wahed & Tsiatis, 2004; Auyeung et al., 2009; Mateos et al.,
2010; Wang et al., 2012), depression (Rush et al., 2004; Kilbourne et al., 2014), schizophrenia
(Schneider et al., 2001), childhood autism (Kasari, 2009), childhood attention deficit hyperactiv-
ity disorder (Nahum-Shani et al., 2012a,b), drug abuse during pregnancy (Jones, 2010), weight
loss (Almirall et al., 2014) and alcoholism (Oslin, 2005). SMART designs involve randomiza-
tion of patients to available treatment options at an initial stage, followed by re-randomizations
at each subsequent stage of some or all of the patients to treatment options available at that stage.
The re-randomizations and the set of treatment options at each stage may depend on information
collected in prior stages such as how well the patient responded to the previous treatment. These
designs attempt to conform better to the clinical practice, but still retain the well-known advan-
tages of randomization over observational studies. A schematic diagram of a SMART design is
presented in Figure 1, where for simplicity of illustration, we have considered only two stages of
treatment; however, SMARTs can have more than two stages in general.
Various outcome types have been considered in the SMART design literature. For example,
both Lavori & Dawson (2004) and Murphy (2005) considered primary analysis of SMART de-
sign with continuous outcomes; details about related sample size calculations under a variety of
research questions were given by Oetting et al. (2011). These sample size calculations were fur-
ther extended to cover binary outcomes by Ghosh et al. (2015). Binary outcomes from a SMART
were analyzed previously via likelihood-based methods by Thall et al. (2000). A lot of attention
in the literature was focussed on analysis of survival outcomes in a SMART (Wahed & Tsiatis,
2004, 2006; Feng & Wahed, 2008; Zhao et al., 2011; Kidwell & Wahed, 2013) and associated
sample size calculations (Feng & Wahed, 2009; Li & Murphy, 2011). Composite outcomes were
considered by Lizotte et al. (2012) and Wang et al. (2012). However, to the best of our knowl-
edge, no one has developed any method for analyzing ordinal outcomes in a SMART design
context till date, even though the outcomes of interest in many clinical and behavioral settings
are measured in an ordinal scale and the methodologies to analyze such data in non-SMART
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Fig. 1: A scheme of a hypothetical SMART design with two stages. The ‘R’ within a circle
represents randomization.
context are available for decades (e.g., Agresti, 1980). The need for analysis methods to deal
with ordinal outcomes in a SMART design has recently been acknowledged by Liu et al. (2014).
The current article aims to address this critical knowledge gap in the literature.
Primary analysis of a SMART often involves comparison of embedded DTRs, the regimes
that are naturally implemented within the trial by design. For example, in the SMART pre-
sented in Figure 1, there are four embedded DTRs, denoted as d(1) = (A,ARAE1−RA), d(2) =
(A,ARAF 1−RA), d(3) = (B,BRBE1−RB ), and d(4) = (B,BRBF 1−RB ), where RA and RB
are the indicators of response (1/0) corresponding to the initial treatments A and B, respectively.
A patient whose treatment sequence is consistent with the regime d(1) is given the treatment A
at the first stage, will continue with the same treatment if s/he is a responder (RA = 1) to it,
else will switch to the treatment E at the second stage if s/he is a nonresponder (RA = 0); other
embedded regimes can be interpreted in a similar fashion. When comparing embedded regimes
in a SMART design of the type presented in Figure 1, one has to consider two types of com-
parison. First, note that among the above four regimes, both d(1) and d(2) start with the same
initial treatment A, and thus the responders at the first stage to A are “shared” between both
these regimes; in other words, the outcome data of the first-stage responders to A will contribute
towards the performance metrics (e.g., mean outcome for continuous data) of both these regimes.
Following Kidwell & Wahed (2013), we call d(1) and d(2) shared-path DTRs. Similarly, d(3) and
d(4) constitute another pair of shared-path DTRs. In contrast, note that d(1) and d(3) (likewise,
d(2) and d(4)) start with different initial treatments, and thus performance metrics of d(1) and d(3)
(likewise, d(2) and d(4)) do not share any common group of trial subjects; they are referred to as
distinct-path DTRs.
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In this article, we will use the well-known Sequenced Treatment Alternatives to Relieve De-
pression (STAR*D) trial (Fava et al., 2003; Rush et al., 2004) for treating depression both to
motivate and to empirically illustrate our methodological developments; see Section 10 for de-
tails about the STAR*D study. Suppose we want to compare any two embedded regimes in
STAR*D, based on their quality of life (QOL) outcome after the use of various treatment se-
quences. In STAR*D, the QOL is an ordinal outcome, taking the ordered categorical values as 1
(very poor), 2 (poor), 3 (fair), 4 (good), and 5 (very good). The existing methods are not tailored
to compare any two embedded regimes with respect to the ordinal variable QOL. However, the
methodologies developed in this article will help to investigate such research questions properly;
see Section 10 for further details.
A simple yet powerful approach to compare ordinal outcomes across two or more groups uti-
lizes a key quantity called the generalized odds ratio (GOR), first introduced by Agresti (1980)
and later employed in the context of standard two-group randomized controlled trials (see, e.g.,
Lui & Chang, 2013). As the name suggests, the GOR is a generalization of the usual odds ratio,
a quantity that is extensively used for binary data, e.g., in case of contingency tables and logistic
regression. Our key contribution in the current article is to generalize the notion ofGOR to more
than one stages of the grouping variable (e.g., treatment) that can be applicable to a SMART de-
sign context; we call the resulting metric the dynamic generalized odds ratio (dGOR).
The main difference between Agresti’s GOR and our newly proposed dGOR is the presence
of the response rate to the initial treatment within the definition of the odds ratio type quantity
(note that these response rates can be different for different embedded regimes, as discussed
in Section 3). Furthermore, as discussed in section 2·1, while the primary purpose of defining
dGOR in the current article is to handle ordinal outcomes in a SMART, the definition of dGOR
does not require the outcome to be ordinal as such; in fact in section 5·2, we show how to com-
pute dGOR for continuous outcomes using U -statistics. Thus the scope of dGOR is very broad,
and it opens up an alternative approach to compare DTRs beyond the standard methods based
on mean outcomes or value functions (eg. Zhao et al., 2012, 2015a,b). We derive the asymp-
totic distribution of the dGOR, using which one can formally test the hypothesis of equality
between two or more embedded DTRs in terms of their dGORs. Interestingly, the comparison
between distinct-path regimes and that between shared-path regimes call for different consider-
ations; hence we deal with these two cases separately. Next, we provide sample size calculation
formula based on dGORs, and validate them via a thorough simulation study. We also extend
the proposed methodology to a K-stage SMART. Furthermore, we develop a basic policy search
algorithm that uses dGOR to find an optimal DTR within a finite class. Finally, we present the
analysis of STAR*D data as an illustration of our proposed methodology. To facilitate wide dis-
semination, we have also developed a web application implementing the methodology, which
is freely available online (https://sites.google.com/site/palashghoshstat/
sample-size-calculator).
The rest of the article is organized as follows: we give a general framework in Section 2; in
Sections 3 and 4, we discuss the comparison of two regimes having different initial treatments
and same initial treatments, respectively; two alternative ways to estimate dGOR is discussed
in Section 5; sample size formula is given in Section 6; we extend the proposed methodology to
a K-stage SMART in Section 7; an algorithm for finding an optimal DTR within a finite class
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using dGOR is presented in Section 8; extensive simulation studies are shown in Section 9 and
STAR*D data is analyzed in Section 10; Section 11 concludes the article with a discussion.
2. A GENERAL FRAMEWORK FOR COMPARING DTRS WITH ORDINAL OUTCOMES
2·1. Dynamic Generalized Odds Ratio
Let Y1 and Y2 be two ordinal random variables, denoting the primary outcomes corresponding
to two groups (e.g., two treatment arms of a clinical trial): group 1 and 2 respectively, each taking
values in J distinct ordered categories, say, 1, . . . , J . Then the generalized odds-ratio (GOR)
between group 2 and group 1 (Agresti, 1980; Lui & Chang, 2013) is defined as GOR(2,1) =
P (Y2>Y1)
P (Y2<Y1)
. The interpretation of GOR is simple. Assuming that a higher category of the outcome
variable is better, GOR > 1 indicates that the group 2 has a better outcome than group 1, and
GOR < 1 indicates the other way round; finally GOR = 1 implies that there is no difference in
outcomes between the two groups. In the following, we extend the above notion to define what
we call a dynamic generalized odds ratio (dGOR), a metric that allows us to compare DTRs
embedded in a SMART with ordinal outcomes.
To formally define the dGOR, we utilize the well-known potential outcomes framework (Ru-
bin, 1974; Robins, 1997). Let T1 and T2 generically denote the treatments given to the patients at
the first and second stages of the SMART considered in Figure 1 respectively, with T1 ∈ {A,B},
T2 ∈ {A,E, F} if T1 = A, and T2 ∈ {B,E, F} if T1 = B. Let YT1T2 be the potential outcome
under the treatment sequence (T1, T2). Note that with respect to the SMART design under con-
sideration, there are only six potential outcomes, viz., YAA, YAE , YAF , YBB, YBE and YBF . Then
the potential outcome under any DTR in the current setup can be written in terms of the above
six potential outcomes, as shown below.
Consider the longitudinal data trajectory (O1, T1, O2, T2, Y ) corresponding to an individual
patient participating in the SMART, where Ok denotes the pre-treatment observations at stage
k (k = 1, 2), Tk is the treatment given at stage k (k = 1, 2) as defined before, and Y is the
primary outcome. Note that the response indicatorRT1 can be subsumed inO2 (RT1 can be either
a component or a low-dimensional summary of the vector-valued O2). Furthermore, define the
history variables as H1 = O1 and H2 = (O1, T1, O2). Any arbitrary DTR g with respect to the
above data structure can be defined as a vector of decision rules, g = (g1, g2), where g1(H1) ∈
A1 and g2(H2) ∈ A2, withAk denoting the class of treatment options at stage k(k = 1, 2). Then
the potential outcome under the arbitrary DTR g can be defined as
Yg = YAAI{g1(H1) = A, g2(H2) = A}
+ YAEI{g1(H1) = A, g2(H2) = E}
+ YAF I{g1(H1) = A, g2(H2) = F}
+ YBBI{g1(H1) = B, g2(H2) = B}
+ YBEI{g1(H1) = B, g2(H2) = E}
+ YBF I{g1(H1) = B, g2(H2) = F},
where I{·} is an indicator function. Now we are in a position to define dGOR as follows.
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DEFINITION 1. Let Yg and Yg′ denote the potential outcomes under two dynamic regimes g
and g′. Then the dynamic generalized odds ratio (dGOR) between g and g′, denoted ηg,g′ , is
defined as
ηg,g′ =
P (Yg > Yg′)
P (Yg < Yg′)
. (1)
where P (Yg > Yg′) is the probability that the outcome for a randomly selected patient from
the set of patients whose treatment sequence is consistent with the regime g is larger than the
outcome for a randomly selected patient from the set of patients whose treatment sequence is
consistent with the regime g′.
Next, we assume that the usual assumptions about potential outcomes (Robins, 1997, 2004)
in a longitudinal setting, viz., (i) consistency and (ii) no unmeasured confounding, hold. Specifi-
cally, the consistency assumption states that the potential outcome under the observed treatment
sequence and the observed outcome agree, i.e., Y = YT1T2 if the observed treatment sequence
is indeed (T1, T2). Thus, while the dGOR is defined conceptually using potential outcomes, it
can be computed based on observed data. On the other hand, the no unmeasured confounding
assumption states that treatment allocation is independent of future potential outcomes given the
history; this is satisfied by design in case of SMARTs (Murphy, 2005).
Remark 1. Even though our main focus in this article is to define and use dGOR for compar-
ing DTRs with ordinal outcomes, the above definition does not require Yg and Yg′ to be ordinal
variables. In fact, as discussed by Agresti (1980) in the context of GOR, the dGOR can as well
be used to compare DTRs based on continuous outcomes. Furthermore, the above definition does
not assume any particular parametric model for the data. Thus the scope of dGOR is very broad,
and it provides an alternative approach to comparing DTRs beyond the standard methods based
on mean potential outcomes or value functions (Zhao et al., 2012, 2015a,b); the value function
of a regime g is defined as E(Yg). Thus, while value-based methods work with mean potential
outcomes, dGOR-based methods work with stochastic ordering of potential outcomes.
Remark 2. In this article, we develop dGOR mainly for a 2-stage SMART. However, in Sec-
tion 7, we derive the dGOR corresponding to any two embedded regimes in a SMART with
more than two stages. In Section 8, we also show how to use dGOR to find an optimal regime
withing a finite class. For a single stage SMART (i.e., an RCT), dGOR becomes GOR.
3. COMPARISON OF TWO DISTINCT-PATH EMBEDDED DYNAMIC REGIMES
3·1. Definition, estimation and asymptotic distribution of dGOR for comparing distinct-path
regimes
Without loss of generality, suppose we are interested in comparing two distinct-path em-
bedded dynamic regimes d(1) = (A,ARAE1−RA) and d(3) : (B,BRBE1−RB ), as previously
defined in Section 1. Here, RA and RB denote the response indicators (1 for responder, 0
for non-responder); note that RA = I{d(1)1 (H1) = d(1)2 (H2) = A} and RB = I{d(3)1 (H1) =
d
(3)
2 (H2) = B}. Also, let Yd(1) denotes the primary outcome of a randomly selected patient from
the set of patients whose treatment sequence is consistent with the regime d(1). Similarly, Yd(3)
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denotes the same corresponds to the regime d(3). Then,
P (Yd(3) > Yd(1))
= P (RARB = 1)× P (Yd(3) > Yd(1) |RARB = 1)
+P (RA(1−RB) = 1)× P (Yd(3) > Yd(1) |RA(1−RB) = 1)
+P ((1−RA)RB = 1)× P (Yd(3) > Yd(1) |(1−RA)RB = 1)
+P ((1−RA)(1−RB) = 1)× P (Yd(3) > Yd(1) |(1−RA)(1−RB) = 1)
=
∑
RA,RB∈{0,1}
J−1∑
u=1
J∑
s=u+1
{
γRAA γ
RB
B (1− γA)1−RA(1− γB)1−RB
×piAARAE1−RA ,upiBBRBE1−RB ,s
}
,
where u corresponds to the regime d(1) and s corresponds to the regime d(3)
piAA,u = piu(T1 = A, T2 = A), piAE,u = piu(T1 = A, T2 = E), piBB,s = pis(T1 = B, T2 = B)
and piBE,s = pis(T1 = B, T2 = E). Similarly P (Yd(3) < Yd(1)) can be computed. Hence, from
(1) the dGOR is given by
ηDPd(3),d(1) =
∑
RA,RB∈{0,1}
J−1∑
u=1
J∑
s=u+1
γRAA γ
RB
B (1− γA)1−RA(1− γB)1−RB × piAARAE1−RA ,upiBBRBE1−RB ,s
∑
RA,RB∈{0,1}
J∑
u=2
u−1∑
s=1
γRAA γ
RB
B (1− γA)1−RA(1− γB)1−RB × piAARAE1−RA ,upiBBRBE1−RB ,s
,(2)
where the superscript “DP” indicates the two regimes under comparison are distinct-path
regimes. The statement ηd(3),d(1) > 1 indicates the regime d
(3) has a better outcome than the
regime d(1) (considering higher values corresponds to better outcomes). Note that, for J = 2,
i.e. for binary outcome data, the above expression boils down to
ηDPd(3),d(1) =
∑
RA,RB∈{0,1}
γRAA γ
RB
B (1− γA)1−RA(1− γB)1−RB × piAARAE1−RA ,1piBBRBE1−RB ,2∑
RA,RB∈{0,1}
γRAA γ
RB
B (1− γA)1−RA(1− γB)1−RB × piAARAE1−RA ,2piBBRBE1−RB ,1
, (3)
which we can call a dynamic odds ratio (dOR). This dOR can reduce to the traditional odds
ratio, piAE,1piBE,2/piAE,2piBE,1, only when there is no split of trial subjects according to their
response/non-response statuses at the end of stage 1 (all non-responders); such a situation arises
in a SMART involving smoking cessation interventions (Strecher et al., 2008; Chakraborty et al.,
2010).
The maximum likelihood estimate of ηDP
d(3),d(1)
, say ηˆDP
d(3),d(1)
, can be computed by plugging-in
the maximum likelihood estimates of γs (empirical response rates) and pis (empirical proba-
bilities of outcome categories) obtained from the likelihood (see Appendix, Section 12·1). The
asymptotic distribution of dGOR in (2) is given by
√
N
(
log(ηˆDP
d(3),d(1)
)− log(ηDP
d(3),d(1)
)
)
→ Normal(0, σ2
d(3),d(1)
), (4)
where N−1σ2
d(3),d(1)
is the variance of log(ηˆDP
d(3),d(1)
). See the Appendix for detailed derivation.
8 P. GHOSH AND B. CHAKRABORTY
Note that, ηDP
d(3),d(1)
in (2) can be alternatively defined as
η
DP
d(3),d(1)
=
∑
RA,RB∈{0,1}
{
γ
RA
A γ
RB
B (1− γA)1−RA (1− γB)1−RB
∑
RA,RB∈{0,1}
{
γ
RA
A γ
RB
B (1− γA)1−RA (1− γB)1−RB
×
[1′(U(Π
AARAE1−RAΠ
′
BBRBE1−RB )− diag(ΠAARAE1−RAΠ
′
BBRBE1−RB ))1]
}
[1′(L(Π
AARAE1−RAΠ
′
BBRBE1−RB
)− diag(Π
AARAE1−RAΠ
′
BBRBE1−RB
))1]
} (5)
where the column vector Π
T1T
RT1
1 T
1−RT1
2
= (Π
T1T
RT1
1 T
1−RT1
2 ,1
, · · · ,Π
T1T
RT1
1 T
1−RT1
2 ,J
)′; d ∈
{d(1), d(3)}. Then U(Z),L(Z) and diag(Z) denote upper-triangular-part, lower-triangular-part
and diagonal-part of a square matrix Z after replacing other elements by zeros, respectively. For
example,
Z =
a b cd e f
g h i
 implies U(Z) =
a b c0 e f
0 0 i
 ,L(Z) =
a 0 0d e 0
g h i
 and diag(Z) =
a 0 00 e 0
0 0 i
 .
The expression of ηDP
d(3),d(1)
in (5) is computationally relatively easy to work with. If we as-
sume the cell probabilities of the ordinal outcome in the two responder arms (and the two non-
responder arms) are same in two embedded distinct-path regimes, then the following theorem
states the relationship between the dGOR and the two response probabilities corresponding to
the two distinct-path regimes.
THEOREM 1. Let ΠAA = ΠBB and ΠAE = ΠBE,
i) then ηDP
d(3),d(1)
= 1 iff γA = γB ,
ii) furthermore, let 1′(U(ΠAAΠ
′
BE)1 ≷ 1′(L(ΠAAΠ
′
BE)1, then η
DP
d(3),d(1)
≷ 1 iff γA ≷ γB .
Proof: i) If part: Let ΠAA = ΠBB, ΠAE = ΠBE and we assume γA = γB . Using the prop-
erty for any square matrix Z, 1′U(Z)1 = 1′L(Z′)1, it is trivial to show that the numerator and
the denominator of ηDP
d(3),d(1)
in (5) are exactly same. Hence, ηDP
d(3),d(1)
= 1.
Only if part: Let ΠAA = ΠBB, ΠAE = ΠBE and ηDPd(3),d(1) = 1, we want to show that γA =
γB . We have
ηDP
d(3),d(1)
= 1
=⇒ γA(1− γB)[1′(U(ΠAAΠ′BE))1] + (1− γA)γB[1′(U(ΠAEΠ
′
BB))1]
= γA(1− γB)[1′(L(ΠAAΠ′BE))1] + (1− γA)γB[1′(L(ΠAEΠ
′
BB))1]
=⇒ γA(1− γB)[1′(U(ΠAAΠ′BE))1− 1′(L(ΠAAΠ
′
BE))1]
= (1− γA)γB[1′(L(ΠAEΠ′BB))1− 1′(U(ΠAEΠ
′
BB))1]
=⇒ γA(1− γB) = (1− γA)γB
=⇒ γA = γB.
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ii) if part: Here we assume γA ≷ γB and show that ηDPd(3),d(1) ≷ 1, respectively. Let γA > γB .
We have
[1′(U(ΠAAΠ
′
BE))1− 1′(L(ΠAAΠ
′
BE))1]
= [1′(L(ΠAEΠ
′
BB))1− 1′(U(ΠAEΠ
′
BB))1] > 0
=⇒ γA(1− γB)[1′(U(ΠAAΠ′BE))1− 1′(L(ΠAAΠ
′
BE))1]
> (1− γA)γB[1′(L(ΠAEΠ′BB))1− 1′(U(ΠAEΠ
′
BB))1]
=⇒ ηDP
d(3),d(1)
> 1.
Similarly, γA < γB implies ηDPd(3),d(1) < 1.
Only if part: This can be proved by replacing “ = ” by “ > ” and “ < ” one at a time in the
only-if-part of i).
In contrast with Theorem 1, if we assume the cell probabilities of the ordinal outcome in the
the responder arm of one regime are same as the cell probabilities of the non-responder arm of
the other regime in two embedded distinct-path regimes, then the following theorem states the
relationship between the dGOR and the two response probabilities corresponding to the two
distinct-path regimes.
THEOREM 2. Let ΠAA = ΠBE and ΠAE = ΠBB,
i) then ηDP
d(3),d(1)
= 1 iff γA = 1− γB ,
ii) furthermore, let 1′(U(ΠAAΠ
′
BB)1 ≷ 1′(L(ΠAAΠ
′
BB)1, then η
DP
d(3),d(1)
≷ 1 iff γA ≷ 1−
γB .
Proof: Following the similar arguments as in the proofs of Theorem 1, Theorem 2 can be
proved.
4. COMPARISON OF TWO SHARED-PATH EMBEDDED DYNAMIC REGIMES
4·1. Definition, estimation and asymptotic distribution of dGOR for comparing shared-path
regimes
In this section, we are interested in comparing two shared-path dynamic regimes, using the
same notations described in Section (3·1) (Kidwell & Wahed, 2013). Without loss of general-
ity, let us consider two shared-path regimes d(1) : (A,ARAE1−RA) and d(2) : (A,AR′AF 1−R′A).
Here, RA = I{d(1)1 (H1) = A, d(1)2 (H2) = A} and R′A = I{d(2)1 (H1) = A, d(2)2 (H2) = A} de-
note the response indicators (1 for responder, 0 for non-responder) for the two randomly selected
patients from the regimes d(1) and d(2), respectively. Also, let Yd(1) and Yd(2) denote their primary
outcomes. Now we have,
P (Yd(2) > Yd(1))
= P (RAR
′
A = 1)× P (Yd(2) > Yd(1) |RAR′A = 1)
+P (RA(1−R′A) = 1)× P (Yd(2) > Yd(1) |RA(1−R′A) = 1)
+P ((1−RA)R′A = 1)× P (Yd(2) > Yd(1) |(1−RA)R′A = 1)
+P ((1−RA)(1−R′A) = 1)× P (Yd(2) > Yd(1) |(1−RA)(1−R′A) = 1).
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Clearly, P (RAR′A = 1) = γ
2
A, P (RA(1−R′A) = 1) = P ((1−RA)R′A = 1) = γA(1− γA),
and P ((1−RA)(1−R′A) = 1) = (1− γA)2. Thus,
P (Yd(2) > Yd(1))
=
∑
RA,R
′
A∈{0,1}
J−1∑
u=1
J∑
s=u+1
γ
RA+R
′
A
A (1− γA)2−RA−R
′
A × piAARAE1−RA ,upiAAR′AF 1−R′A ,s
Similarly P (Yd(2) < Yd(1)) can be computed. Hence, from (1) the dGOR is given by
ηSPd(2),d(1) =
∑
RA,R
′
A
∈{0,1}
J−1∑
u=1
J∑
s=u+1
γ
RA+R
′
A
A (1− γA)2−RA−R
′
A × piAARAE1−RA ,upiAAR′AF1−R′A ,s∑
RA,R
′
A
∈{0,1}
J∑
u=2
u−1∑
s=1
γ
RA+R
′
A
A (1− γA)2−RA−R
′
A × piAARAE1−RA ,upiAAR′AF1−R′A ,s
, (6)
where the superscript “SP” indicates that the two regimes under comparison are shared-path
regimes.
Remark 3. The dGOR, ηSP
d(2),d(1)
given in (6) to compare two shared-path regimes is a special
case of dGOR, ηDP
d(3),d(1)
defined in (2); ηSP
d(2),d(1)
can be obtained from the ηDP
d(3),d(1)
by replacing
d(3), γB and RB by d(2), γA and R′A, respectively.
Note that ηSP
d(2),d(1)
in (6) can be alternatively defined as
ηSPd(2),d(1)
=
∑
RA,R
′
A
∈{0,1}
γA(RA, R
′
A)[1
′(U(ΠAARAE1−RAΠ
′
AA
R′
AF
1−R′
A
)− diag(ΠAARAE1−RAΠ
′
AA
R′
AF
1−R′
A
))1]∑
RA,R
′
A
∈{0,1}
γA(RA, R′A)[1′(L(ΠAARAE1−RAΠ
′
AA
R′
AF
1−R′
A
)− diag(ΠAARAE1−RAΠ′
AA
R′
AF
1−R′
A
))1]
,
where γA(RA, R′A) = γ
RA+R
′
A
A (1− γA)2−RA−R
′
A .
The maximum likelihood estimate of ηSP
d(2),d(1)
, say ηˆSP
d(2),d(1)
, can be computed by plugging-in
the maximum likelihood estimates of γs (empirical response rates) and pis (empirical probabili-
ties of outcome categories), as before. The asymptotic distribution is given by
√
N
(
log(ηˆSP
d(2),d(1)
)− log(ηSP
d(2),d(1)
)
)
→ Normal(0, σ2
d(2),d(1)
), (7)
where N−1σ2
d(2),d(1)
is the variance of log(ηˆSP
d(2),d(1)
). See the Appendix for detailed derivation.
Remark 4. Note that, ΠAE = ΠAF implies ηSPd(2),d(1) = 1. However, the converse is not
true. We illustrate this point with the following example. Let ΠAA = (0.2, 0.3, 0.5), ΠAE =
(0.12, 0.32, 0.56), ΠAF = (0.06, 0.41, 0.53) and γA = 0.2, here dGOR = 1 even though
ΠAE 6= ΠAF. Also ηSPd(2),d(1) is not invariant in ΠAA. Consider two values of ΠAA as
(0.5, 0.4, 0.1) and (0.2, 0.4, 0.4). It can be shown that for γA = 0.2, ηSPd(2),d(1) values are dif-
ferent in two cases (0.43 and 0.45) when both ΠAE and ΠAF are fixed at (0.3, 0.3, 0.4) and
(0.6, 0.2, 0.2), respectively.
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5. ALTERNATIVE WAYS TO ESTIMATE dGOR
5·1. dGOR based on Concordant and Discordant pairs
Goodman & Kruskal (1954) proposed a measure of association Γ for a I × J cross-classified
table; where I represents the number of ordinal categories of the row variable and J denotes the
same for the column variable. The Goodman-Kruskal Γ is based on the number of concordant
and discordant pairs corresponding to any two individuals randomly chosen from the popula-
tion. Let the two chosen individuals be denoted by (i, j) and (i′, j′), where i, i′ = 1, · · · , I and
j, j′ = 1, · · · , J . The chosen pair (two individuals) is called concordant if (i < i′ and j < j′)
or (i > i′ and j > j′). On the other hand, the chosen pair is discordant if (i < i′ and j > j′) or
(i > i′ and j < j′). Note that, the GOR described in the current article is not defined for a I × J
cross-classified table; rather, we can think of a 2× J table where two rows denote two different
sub-populations (e.g., two arms of a trial) and the columns correspond to the J ordered categories
of an ordinal variable Y . However, we can calculate GOR based on the number of concordant
and discordant pairs in a slightly different manner. Suppose a randomly selected individual from
the first row (say, sub-population 1) is denoted by (1, u) and similarly, a randomly selected
individual from the second row (say, sub-population 2) is denoted by (2, s); u, s = 1, · · · , J .
Define the randomly selected pair (with respect to GOR(2,1)) to be concordant if u < s, i.e.,
the individual selected from population 2 has higher response category than the individual se-
lected from population 1. Under the same setup, define the pair to be discordant if u > s. Thus,
the total number of concordant and discordant pairs are given by
∑J−1
u=1
∑J
s=u+1 n1un2s and∑J
u=2
∑u−1
s=1 n1un2s, respectively, where nik denotes the cell frequency corresponding to the
ith sub-population and the kth ordinal category with i = 1, 2; k = 1, · · · , J . An estimate of the
probability P (Y2 > Y1) can be given as 1n1·n2·
∑J−1
u=1
∑J
s=u+1 n1un2s, where ni· =
∑J
u=1 niu,
i = 1, 2. We can write GOR(2,1) as the ratio of the total number of concordant pairs over the
total number of discordant pairs as
ĜOR(2,1) =
∑J−1
u=1
∑J
s=u+1 n1un2s∑J
u=2
∑u−1
s=1 n1un2s
.
In a similar fashion, we can easily express the estimate of dGOR defined in (2) as
ηˆDP
d(3),d(1)
=
J−1∑
u=1
J∑
s=u+1
[
nAA,unBB,s + 2× nAA,unBE,s + 2× nAE,unBB,s + 4× nAE,unBE,s
]
J∑
u=2
u−1∑
s=1
[
nAA,unBB,s + 2× nAA,unBE,s + 2× nAE,unBB,s + 4× nAE,unBE,s
] , (8)
where nAA,u denotes the cell frequency of the uth ordinal category in the responder arm of
the regime d(1); other cell frequencies are defined accordingly. Note that, total number of in-
dividuals in the responder arm of the regime d(1) is nAA· =
∑J
u=1 nAA,u =
N
2 × γˆA, where
N is the known total number of individuals in the entire SMART. In (8), the four com-
ponents in the numerator (or the denominator) refer to the four different ways of choosing
a pair of individuals from the two regimes d(1) and d(3). Specifically, we have the set as
{(AA,BB), (AA,BE), (AE,BB), (AE,BE)}, where (AE,BB) refers to an individual who
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is randomly chosen from the non-responder arm of the regime d(1) and the other individual is
randomly chosen from the responder arm of the regime d(3). Intuitively, ηˆDP
d(3),d(1)
is the ratio of
the weighted sum of the concordances to the weighted sum of the discordances. Here, the weight
is a product of the number of times each of the selected two individuals in the pair is randomized.
For example, if the pair is coming from (AE,BB), the weight is 2× 1 because the individual
from the regime d(1) is a non-responder and hence randomized twice whereas the other individ-
ual from the regime d(3) is a responder and hence randomized only once in the study. Giving a
higher weight to a non-responder makes sense in order to account for the structural imbalance
between responders and non-responders inherently present in the “restricted” SMART design
considered here (Figure 1) (Robins, 1997; Murphy, 2005; Nahum-Shani et al., 2012a). However,
for the “unrestricted” SMART design (Collins, 2018) where both responders and non-responders
are evenly randomized (See Supplementary Material Figure 1), no such weighting is necessary.
The use of the notion of concordance in the DTR literature is not new; see Fan et al. (2017) and
Liang et al. (2018) for concordance-assisted learning for optimal treatment regimes.
5·2. dGOR for continuous outcome based on U-statistic
As mentioned in Section 2·1, Remark 1, dGOR can also be defined for continuous outcomes.
Specifically, we can write the dGOR defined in (1) to compare the regimes d(3) and d(1) in a
SMART with continuous outcome as
ηd(3),d(1) =
P (Yd(3) > Yd(1))
1− P (Yd(3) > Yd(1))
,
Note that, the P (Yg > Yg′) can be estimated by using the U -statistic
1
nd(3)nd(1)
n
d(3)∑
s=1
n
d(1)∑
u=1
φ(Yd(3)s;Yd(1)u), (9)
where nd(3) and nd(1) denote the total number of people with treatment sequences consistent
with the regimes d(3) and d(1), respectively; Yd(3)s denotes the primary outcome of s
th individual
corresponding to the regime d(3); and
φ(Yd(3)s;Yd(1)u) =
∑
RB ,RA∈{0,1}
γRAA γ
RB
B (1− γA)1−RA(1− γB)1−RB
×I(YBBRBE1−RB ,s > YAARAE1−RA ,u), (10)
where I(·) is an indicator function; YBE,s denotes the primary outcome of sth individual with re-
sponder statusRB = 0 (i.e, (T1, T2) = (B,E)) corresponding to the regime d(3). The U -statistic
in (9) is a multi-sample U -statistic with E(φ(Yd(3)s;Yd(1)u)) = P (Yd(3) > Yd(1)) and φ(·; ·) is
symmetric by default as it contains only one argument from each of the two samples (Lehmann,
1998).
6. PRIMARY ANALYSIS AND SAMPLE SIZE FORMULA
Specifying a primary analysis is necessary for a SMART in order to power it (Murphy, 2005).
In the present context, we first consider the primary analysis to test if the regime d(3) differs from
the regime d(1) in terms of the ordinal primary outcome (comparison of distinct-path embed-
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ded regimes). Consider the null hypothesis as H0 : log ηDPd(3),d(1) = 0 vs H1 : log η
DP
d(3),d(1)
= δ,
or equivalently H0 : ηDPd(3),d(1) = 1 against the alternative hypothesis H1 : η
DP
d(3),d(1)
= eδ, where
δ could take any positive or negative value. Using the asymptotic distribution of log(ηˆDP
d(3),d(1)
) in
(4) we use log(ηˆDP
d(3),d(1)
) as the test statistics for the primary analysis. For a positive (negative)
value of δ, the high positive (negative) value of log(ηˆDP
d(3),d(1)
) is an indicator of departure from
the null hypothesis. Let zα/2 be the (1− α/2) percentile of the standard normal distribution and
set the power of the test as 1− β, where β is the type-II error. Using (4) the required sample size
is given by
N = (zα/2 + zβ)
2
σ2
d(3),d(1)
δ2
. (11)
HereN is the total number of patients in the trial. We can consider δ/σd(3),d(1) as the standardized
effect size, which can potentially be elucidated from scientific investigators prior to designing the
SMART.
The primary analysis and the sample size formula for the shared-path setup are similar to the
above with replacement of log ηDP
d(3),d(1)
and σ2
d(3),d(1)
by log ηSP
d(2),d(1)
and σ2
d(2),d(1)
, respectively.
7. EXTENSION TO K-STAGE SMART
The proposed methodology can be extended to a K-stage SMART, for K > 2. Here, for gen-
erality, we assume K ≥ 2. In general, a K-stage DTR is of the form g = (g1, · · · , gK) where
gk is the treatment decision at stage k (k = 1, · · · ,K). Then the potential outcome under the
regime g is
Yg =
∑
(t1,··· ,tK)
Yt1,··· ,tKI{g1(H1) = t1, · · · , gK(HK) = tK},
where Yt1,··· ,tK is the potential outcome under the treatment sequence (t1, · · · , tK).
Following the same structure as in Figure 1, we can postulate a K-stage SMART that starts
with two initial treatments A1 or B1. For simplicity of notation, we will only discuss the com-
parison of two distinct-path regimes. Comparison of two shared-path regimes in a K-stage setup
can be addressed similarly. Suppose in the regime g′, a patient starts with the initial treatment
A1, continues the same treatment Ak−1 at the kth(k = 2, · · · ,K) stage if s/he is a responder or
switches to the treatment Ak if s/he is a non-responder to the previous stage treatment. Similarly
in the regime g, suppose a patient starts with the initial treatment B1, continues the same treat-
ment Bk−1 at the kth(k = 2, · · · ,K) stage if s/he is a responder or switches to the treatment
Bk if s/he is a non-responder to the previous stage treatment. Define the response rates after
getting treatment Ak and Bk as γAk and γBk , respectively for k = 1, · · · ,K − 1; correspond-
ing response indicators are RAk and RBk , respectively. Let Yg(K) and Yg′(K) be the potential
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outcomes for regimes g and g′, respectively. Similar to Section 3·1, here we have
P (Yg(K) > Yg′(K))
=
∑
RA1 ,··· ,RAk′∈{0,1}
RB1 ,··· ,RBk∈{0,1}
k′,k=2,··· ,K
J−1∑
u=1
J∑
s=u+1
{
γ
RAk′−1
Ak′−1
(1− γAk′−1)
1−RAk′−1
× (1− γAk′−2) · · · (1− γA1)
}
×
{
γ
RBk−1
Bk−1 (1− γBk−1)
1−RBk−1 (1− γBk−2) · · · (1− γB1)
}
×piAk′−1,upiBk−1,s, (12)
and
P (Yg(K) < Yg′(K))
=
∑
RA1 ,··· ,RAk′∈{0,1}
RB1 ,··· ,RBk∈{0,1}
k′,k=2,··· ,K
J∑
u=2
u−1∑
s=1
{
γ
RAk′−1
Ak′−1
(1− γAk′−1)
1−RAk′−1
× (1− γAk′−2) · · · (1− γA1)
}
×
{
γ
RBk−1
Bk−1 (1− γBk−1)
1−RBk−1 (1− γBk−2) · · · (1− γB1)
}
×piAk′−1,upiBk−1,s, (13)
where
piBk−1,s = piB1B
RB1
1 B
1−RB1
2 B
(1−RB1 )RB2
2 B
(1−RB1 )(1−RB2 )
3 ······
B
(1−RB1 )···(1−RBk−1 )RBk−1
k−1 B
(1−RB1 )···(1−RBk−1 )(1−RBk−1 )
k , s
denotes the sth cell probability of a responder or non-responder after kth stage for (1−
RB1) · · · (1−RBk−1)RBk−1 = 1 or (1−RB1) · · · (1−RBk−1)(1−RBk−1) = 1, respectively.
Similarly, piAk′−1,u is also defined. Thus we define the K-stage dGOR, for K ≥ 2, to compare
two distinct-path regimes g with g′ as
η
DP (K)
g,g′ =
P (Yg(K) > Yg′(K))
P (Yg(K) < Yg′(K))
. (14)
Note that, when K = 2, the above dGOR, ηDP (K)g,g′ boils down to η
DP
d(3),d(1)
with g = 3 and g′ =
1 as defined in (2). The asymptotic variance of log(ηˆDP (K)g,g′ ) is given by N
−1σ2g,g′(K) (See
appendix).
8. FINDING AN OPTIMAL DTR WITHIN A FINITE CLASS USING dGOR
So far in the current article, we have focused on comparing embedded regimes within a
SMART. Now we illustrate how the concept of dGOR, coupled with a policy search approach,
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can potentially help to find an optimal DTR within a finite class (Zhao et al., 2012, 2015a,b;
Zhang et al., 2012; Laber et al., 2018).
Consider a finite class of regimes G = {g(1), g(2), · · · , g(m)}, where each member regime
g(m),m = 1, · · · ,M , consists of K decision rules corresponding to K stages of intervention,
g(m) = (g
(m)
1 , · · · , g(m)K ). Utilizing previously explained notations, the potential outcome Yg(m)
can be written as
Yg(m) =
∑
(t1,··· ,tK)
Yt1,··· ,tKI{g(m)1 (H1) = t1, · · · , g(m)K (HK) = tK}.
Then the dGOR between two member regimes g(m) and g(m
′) can be defined as
ηg(m),g(m′) =
P (Yg(m) > Yg(m′))
P (Yg(m) < Yg(m′))
. (15)
Once we define the dGORs between any pair of regimes (g(m), g(m
′)), we can apply some policy
search method to find gopt ∈ G. In the following, we present a basic algorithm to illustrate the
idea.
1: Initialize gopt ← g(1), Gsearch = G − {g(1)}
2: If ηgopt,g(2) > 1 significantly, then Gsearch = Gsearch − {g(2)}
else Gsearch = Gsearch − {g(2)} and gopt ← g(2)
3: If ηgopt,g(3) > 1 significantly, then Gsearch = Gsearch − {g(3)}
else Gsearch = Gsearch − {g(2)} and gopt ← g(3)
4: Continue till Gsearch = ∅, the empty set.
Output: gopt
Note that since decisions at each step are based on hypothesis testing, one should adjust for
multiple testing, e.g. via Bonferroni correction.
9. SIMULATION STUDIES
In this section, we present two thorough simulation studies to illustrate the performance of
the methodologies proposed above. Specifically, Section 9·1 presents the performance of the
dGOR-based estimation and inference in case of distinct-path dynamic regimes (cf. Section 3);
Section 9·2 involves the performance of dGOR in case of shared-path dynamic regimes (cf. Sec-
tion 4); Section 9·3 illustrates performance of dGOR in few scenarios where one or more arms
(responder or non-responder) of the two regimes contain some small cell probabilities. The de-
tails of the data generation process have been described in Supplementary Material. The response
rates corresponding to initial treatments A and B are taken as γA = 0.3 and γB = 0.4, respec-
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tively. Simulations considering different values of response rates are shown in Supplementary
Material. We assume the type-I error rate as 0.05 and the nominal power as 0.80.
9·1. Simulation study for distinct-path regimes
This study aims to assess the performance of ηDP
d(3),d(1)
in comparing two distinct-path
embedded regimes d(1) and d(3). We consider an ordinal outcome with J = 3 categories
in ascending order. For regime d(1), the cell probabilities of the primary outcome are
given by pi(A,A) = (piAA,1, piAA,2, 1− piAA,1 − piAA,2) for the responders and pi(A,E) =
(piAE1, piAE2, 1− piAE1 − piAE2) for the non-responders. Likewise, for regime d(3), the corre-
sponding cell probabilities are pi(B,B) = (piBB1, piBB2, 1− piBB1 − piBB2) for the responders
and pi(B,E) = (piBE1, piBE2, 1− piBE1 − piBE2) for the non-responders. The serial number
(SL) in the first column of Table 1 shows the six different scenarios. The first three of them cor-
respond to ηDP
d(3),d(1)
> 1 and the last three correspond to ηDP
d(3),d(1)
< 1. Here ηDP
d(3),d(1)
denotes the
true values of corresponding population dGOR. We obtain the true value of dGOR (ηDP
d(3),d(1)
)
by using Monte Carlo computation considering a ‘large’ population of size of 106. Figure 2(a)
shows the plot of barycentric coordinates of the probabilities from the six different scenarios
in Table 1 (Jupp et al., 2012). Any three probabilities of the form (p1, p2, 1− p1 − p2) can be
represented by a unique point in an equilateral triangle in a barycentric coordinate system. Three
vertices are denoted by (1, 0, 0), (0, 1, 0) and (0, 0, 1). In a barycentric coordinate plot, a point
(p1, p2, 1− p1 − p2) can be located by considering i) a distance p1 from the opposite arm of the
vertex (1, 0, 0), ii) a distance p2 from the opposite arm of the vertex (0, 1, 0), and, iii) a distance
1− p1 − p2 from the opposite arm of the vertex (0, 0, 1). The objective of the Figure 2(a) is to
show how the six simulation scenarios in Table 1 are distributed in the barycentric coordinate
system.
In Table 1, the ‘Std. ES’ denotes the standardized effect size which is calculated as log ηDP
d(3),d(1)
divided by the square root of the variance of log ηDP
d(3),d(1)
; N denotes the estimated sample size.
Based on the 5,000 simulations, ηˆDP
d(3),d(1)
is the estimated value of ηDP
d(3),d(1)
; SSE is the sample
standard error; ASE is the asymptotic standard error; p̂ower is the estimated power and ĈP
is the estimated coverage probability. In Table 1, ηˆDP
d(3),d(1)
is close to its true value in all the six
scenarios, indicating good estimation. The estimated sample sizeN varies from 164 to 571 when
ηDP
d(3),d(1)
> 1 and from 305 to 1096 when ηDP
d(3),d(1)
< 1. Note that, N is a decreasing function of
the absolute value of the standardized effect size. However, we can have the same standardized
effect size for different combinations of ηDP
d(3),d(1)
, the response rates and the cell probabilities
corresponding to the two regimes. The SSE and ASE are close to each other in all the scenarios.
The estimated empirical powers and the coverage probabilities are close to their corresponding
nominal values in all the cases.
9·2. Simulation study for shared-path regimes
In this section we consider the simulation study to compare the shared-path regimes d(1)
and d(2) that start with the same initial treatments, as discussed in the section 4. Similar to
the previous section, here also, we set the number of categories of the ordinal outcome vari-
able as J = 3 in ascending order. For regime d(2), the cell probabilities of primary outcome
are given by pi(A,A) = (piAA,1, piAA,2, 1− piAA,1 − piAA,2) for the responders and pi(A,F ) =
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Fig. 2: Corresponding to Tables 1 and 2, the Barycentric plots of different multinomial probabil-
ities for comparing (a) distinct-path regimes, •: pi(A,A) , •: pi(A,E), •: pi(B,B), •: pi(B,E);
and (b) shared-path regimes, •: pi(A,A) , •: pi(A,E), •: pi(A,F ).
Table 1: Comparison of Distinct-path regimes with ordinal outcome. Here, γA = 0.3 and γB =
0.4, nominal power is 0.80 and type-I is 0.05. The standardized effect size is in log-scale. Esti-
mated power and coverage probability are based on 5,000 simulations.
SL pi(A,A) pi(B,B) Std. ES2 ηDP
d(3),d(1)
N ηˆDP
d(3),d(1)
SSE ASE p̂ower ĈP
pi(A,E) pi(B,E) (log scale)
1 (0.23, 0.51, 0.26) (0.31, 0.50, 0.19)
(0.50, 0.41, 0.09) (0.14, 0.47, 0.39) 0.219 2.55 164 2.72 1.06 1.14 0.78 0.94
2 (0.41, 0.23, 0.36) (0.50, 0.22, 0.28)
(0.58, 0.20, 0.22) (0.27, 0.22, 0.51) 0.147 1.86 366 1.89 0.43 0.43 0.78 0.95
3 (0.21, 0.40, 0.39) (0.28, 0.41, 0.31)
(0.30, 0.41, 0.29) (0.12, 0.34, 0.54) 0.117 1.64 571 1.66 0.29 0.30 0.79 0.95
4 (0.13, 0.22, 0.65) (0.10, 0.19, 0.71)
(0.09, 0.18, 0.73) (0.20, 0.26, 0.54) -0.085 0.66 1096 0.67 0.10 0.10 0.78 0.95
5 (0.12, 0.24, 0.64) (0.09, 0.21, 0.70)
(0.07, 0.18, 0.75) (0.18, 0.28, 0.54) -0.099 0.61 797 0.61 0.12 0.11 0.82 0.95
6 (0.28, 0.52, 0.20) (0.34, 0.50, 0.16)
(0.08, 0.43, 0.49) (0.20, 0.52, 0.28) -0.161 0.50 305 0.53 0.26 0.16 0.81 0.94
(piAF,1, piAF,2, 1− piAF,1 − piAF,2) for the non-responders. Note that, pi(A,A) corresponds to
both regimes d(1) and d(2) (shared-path). The barycentric coordinate plot in Figure 2(b) shows
how the six simulation scenarios in Table 2 are distributed in the barycentric coordinate system.
Table 2 shows the results of six scenarios for shared-path comparison of two regimes. Similar
to previous section, the first three scenarios correspond to ηSP
d(2),d(1)
> 1 and the last three sce-
narios to ηSP
d(2),d(1)
< 1. The estimated sample size N ranges from 304 to 659 when ηSP
d(2),d(1)
> 1
and from 241 to 1218 when ηSP
d(2),d(1)
< 1. In all the six scenarios, the SSE and the ASE are close
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Table 2: Comparison of Shared-path regimes with ordinal outcome. Here, γA = 0.3 and γB =
0.4, nominal power is 0.80 and type-I is 0.05. The standardized effect size is in log-scale. Esti-
mated power and coverage probability are based on 5,000 simulations.
SL pi(A,A) Std. ES ηSP
d(2),d(1)
N ηˆSP
d(2),d(1)
SSE ASE p̂ower ĈP
pi(A,E) pi(A,F ) (log scale)
1 (0.24, 0.52, 0.24)
(0.63, 0.33, 0.04) (0.38, 0.49, 0.13) 0.161 1.88 304 1.94 0.44 0.49 0.77 0.97
2 (0.03, 0.66, 0.31)
(0.19, 0.74, 0.07) (0.07, 0.75, 0.18) 0.148 1.96 357 1.97 0.54 0.51 0.77 0.94
3 (0.43, 0.17, 0.40)
(0.73, 0.12, 0.15) (0.56, 0.16, 0.28) 0.109 1.56 659 1.60 0.26 0.27 0.81 0.96
4 (0.36, 0.36, 0.28)
(0.40, 0.35, 0.25) (0.52, 0.32, 0.16) -0.080 0.73 1218 0.73 0.08 0.09 0.80 0.95
5 (0.17, 0.10, 0.73)
(0.15, 0.10, 0.75) (0.29, 0.13, 0.58) -0.113 0.58 618 0.58 0.12 0.12 0.82 0.94
6 (0.24, 0.35, 0.41)
(0.16, 0.32, 0.52) (0.38, 0.35, 0.27) -0.181 0.50 241 0.50 0.13 0.14 0.80 0.96
to each other. The estimated empirical powers and the coverage probabilities are close to their
corresponding nominal values.
In summary, from both the simulation studies in Sections 9·1 and 9·2, it is evident that the
proposed dGORs for comparing both distinct-path and shared-path regimes perform well.
9·3. Simulation study with smaller cell probabilities
In general, the maximum likelihood estimate of a small cell probability (say less than 5%)
may end up with large bias due to less number of individuals in that cell. These biases in esti-
mated cell probabilities make the corresponding estimated power and CP to deviate from their
nominal values. Note that, the estimation problem related to a small probability/frequency is
well known in the inference of categorical data (Yates, 1934; Agresti, 1990). In Table 3, we have
considered similar scenarios to explore how our methodologies work. In all the five scenarios of
Table 3, some of the cell probabilities are less than 5% or close to it. In Figures 3(a) and (b),
we have shown how the five simulation scenarios from Table 3 are distributed in the barycentric
coordinate system.
The estimated power and CP deviate from their respective values. In scenario 1 for distinct-
path comparison, the estimated value of dGOR is almost same as the population dGOR. As
expected, the estimated power and CP are not much less than their nominal values. However,
in all the other four scenarios, either power or CP or both are far apart from their respective
nominal values. The estimated power is 0.39 in scenario 3 of distinct-path comparison where the
last two cell probabilities of pi(A,E) are 0.03 and 0.02, respectively. In summary, when the cell
probabilities of some cells corresponding to a regime become less than 5%, the estimated dGOR
should be interpreted with caution.
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Table 3: Some examples with small cell probabilities. Here, γA = 0.3 and γB = 0.4, nominal
power is 0.80 and type-I is 0.05. The standardized effect size is in log-scale. Estimated power
and coverage probability are based on 5,000 simulations.
SL pi(A,A) pi(B,B) Std. ES ηDP
d(3),d(1)
N ηˆDP
d(3),d(1)
SSE ASE p̂ower ĈP
pi(A,E) pi(B,E) (log scale)
Comparison of distinct-path:
1 (0.04, 0.87, 0.09) (0.07, 0.88, 0.05)
(0.06, 0.88, 0.06) (0.02, 0.82, 0.16) 0.072 1.68 1506 1.67 0.39 0.32 0.77 0.92
2 (0.06, 0.55, 0.39) (0.04, 0.49, 0.47)
(0.02, 0.40, 0.58) (0.12, 0.63, 0.26) -0.156 0.48 322 1.73 2.63 3.29 0.79 0.56
3 (0.81, 0.11, 0.08) (0.87, 0.08, 0.05)
(0.95, 0.03, 0.02) (0.69, 0.16, 0.15) 0.170 3.23 272 3.63 2.06 10.7 0.39 0.97
Comparison of Shared-path:
pi(A,A) ηSP
d(2),d(1)
ηˆSP
d(2),d(1)
pi(A,E) pi(A,F )
1 (0.03, 0.82, 0.15)
(0.19, 0.79, 0.02) (0.06, 0.86, 0.08) 0.137 2.23 420 2.16 0.74 0.71 0.74 0.87
2 (0.06, 0.47, 0.47)
(0.02, 0.33, 0.65) (0.12, 0.57, 0.31) -0.219 0.38 164 1.87 1.43 1.16 0.74 0.43
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Fig. 3: Corresponding to Table 3, the Barycentric plots of different multinomial probabilities for
comparing (a) distinct-path, •: pi(A,A) , •: pi(A,E), •: pi(B,B), •: pi(B,E); and (b) shared-
path regimes, •: pi(A,A) , •: pi(A,E), •: pi(A,F ).
10. APPLICATION TO STAR*D DATA
In this section, we demonstrate how the developed dGOR can be used to compare any two
different embedded regimes in a two-stage SMART for treating depressive disorder based on
STAR*D data. In this study, there were four stages/levels of intervention, with a total sample
size of 4041. For illustration purpose, we have not considered level 4 of the STAR*D in the cur-
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rent analysis. We consider the data from level 1 as the baseline characteristics since in this level
all the patients were given citalopram (CIT) without any randomization. Symptom severity was
measured by quick inventory of depressive symptomatology (QIDS) score. At every level, pa-
tients who had QIDS less than or equal to 5 were considered responders, only the non-responders
were eligible to enter the next level of the study. The non-responders at the end of level 1 entered
level 2 where they were randomized to either (a) mono therapy, denoted as ‘M ’, which includes:
bupropion – sustained release (BUP-SR) or sertraline (SER) or venlafaxine – extended release
(VEN-XR) or cognitive psychotherapy (CT); or (b) combination therapy, denoted as ‘C’, which
includes: CIT + BUP-SR, or CIT+ buspirone (BUS), or CIT + CT. Patients who were given CT
or CIT+CT at level 2 and who had non-satisfactory response were eligible to enter a supplemen-
tary level 2A with treatment options VEN-XR or BUP-SR. Patients not responding satisfactorily
at level 2 (and level 2A, if applicable) would continue to level 3, where for randomization, the
mono therapy options were mirtazapine (Mirt) or nortriptyline (NTP), whereas the combination
therapy options were either lithium (Li) or thyroid hormone (Thy) combined with treatments
given at the previous level. In this analysis, we consider the levels 2 and 2A as a single level. In
other words, a patient who entered level 2A is considered to have obtained combination therapy.
We rename the level 2 + 2A as stage 1 and level 3 as stage 2 (Chakraborty et al., 2016). Note that,
in STAR*D, the responders did not receive any treatment, but they were followed for 12 months
(Rush et al., 2004). In summary, for the analysis considered here from the STAR*D study, at
the first stage, patients were randomized between mono or combination therapies, the responders
from stage 1 were followed for 12 months and the non-responders were re-randomized between
mono or combination therapies at the second stage. In other words, the data setup from STAR*D
is consistent with Figure 1.
In Section 1, we have considered four embedded regimes based on Figure 1.
Given the above setup, the four embedded regimes in the STAR*D study are
(M,FURMM1−RM ), (M,FURMC1−RM ), (C,FURCM1−RC ), and (C,FURCC1−RC ),
where FU denotes 12 months follow up for responders and RM and RC are the responser
statuses (1 = responder and 0 = non-responder). The outcome of interest is the quality of life
(QOL), an ordinal variable with the levels 1 (very poor), 2 (poor), 3 (fair), 4 (good), and 5 (very
good). In each stage, the outcome data (QOL) were recorded only for the non-responders from
the previous-stage (Chakraborty et al., 2016). Following Chakraborty & Moodie (2013), we
consider the overall QOL for each subject as
Y = RY1 + (1−R)
(
Y1 + Y2
2
)
, (16)
where Y1 and Y2 are the QOL at the end of stages 1 and 2, respectively, R ∈ {RM , RC}. From
the five categories of QOL in STAR*D and using (16), for the illustration purpose, we construct
three new categories of QOL as poor (Y < 3), fair (Y = 3) and good (Y > 3). An analysis
considering four categories of the QOL is described in the Supplementary Material.
In Table 4, we have shown the different comparison of regimes from STAR*D data. Note
that, there are four different pairs of distinct-path regimes and two different pairs of shared-
path regimes. Among the first four comparison of distinct-path regimes in Table 4, only the first
two have statistically significant dGOR (confidence intervals (CIs) of the corresponding log of
dGOR do not contain 0). Based on these dGORs, one can infer that giving combination ther-
SMART with Ordinal Outcome 21
apies (C) at both stages or at least switch to monotherapy (M ) at the second stage are better
options than giving monotherapies at both stages. On the other hand, among the two different
shared-path comparisons in the last two entries of Table 4, only the first one is statistically sig-
nificant (with respect to log of dGOR). In other words, we can conclude that it is better to switch
to combination therapy (C) for a patient who is a non-responder after having monotherapy (M )
at the first stage.
Table 4: Comparison of regimes with quality of life (QOL) as the ordinal outcome in STAR*D
data. Here, M : monotherapy, C : combination therapy and FU : follow up. The response rates
are γM = 0.32 and γC = 0.45, following the first-stage treatment M and C respectively. Note
that, dGOR2,1 = P (YRegime(2) > YRegime(1))/P (YRegime(2) < YRegime(1)).
Regime(1) Regime(1).prob: Regime(2) Regime(2).prob: dGOR2,1 log.dGOR2,1 CI.log.dGOR2,1
(Responder) (Responder)
(Non-Responder) (Non-Responder)
Comparison of distinct-path regimes
(M,FURMM1−RM ) ( 0.08, 0.33, 0.59 ) (C, FURCM1−RC ) ( 0.10, 0.30, 0.60 ) 1.43 0.36 ( 0.06, 0.66 )
( 0.50, 0.34, 0.16 ) ( 0.41, 0.39, 0.20 )
(M,FURMM1−RM ) ( 0.08, 0.33, 0.59 ) (C, FURCC1−RC ) ( 0.10, 0.30, 0.60 ) 1.36 0.31 ( 0.01, 0.61 )
( 0.50, 0.34, 0.16 ) ( 0.46, 0.32, 0.21 )
(M,FURMC1−RM ) ( 0.08, 0.33, 0.59 ) (C, FURCM1−RC ) ( 0.10, 0.30, 0.60 ) 0.92 -0.08 ( -0.39, 0.23 )
( 0.39, 0.25, 0.36 ) ( 0.41, 0.39, 0.20 )
(M,FURMC1−RM ) ( 0.08, 0.33, 0.59 ) (C, FURCC1−RC ) ( 0.10, 0.30, 0.60 ) 0.89 -0.11 ( -0.43, 0.20 )
( 0.39, 0.25, 0.36 ) ( 0.46, 0.32, 0.21 )
Comparison of shared-path regimes
(M,FURMM1−RM ) ( 0.08, 0.33, 0.59 ) (M,FURMC1−RM ) ( 0.08, 0.33, 0.59 ) 1.52 0.42 ( 0.07, 0.77 )
( 0.50, 0.34, 0.16 ) ( 0.39, 0.25, 0.36 )
(C,FURCM1−RC ) ( 0.10, 0.30, 0.60 ) (C,FURCC1−RC ) ( 0.10, 0.30, 0.60 ) 0.96 -0.04 ( -0.30, 0.22 )
( 0.41, 0.39, 0.20 ) ( 0.46, 0.32, 0.21 )
11. DISCUSSION
The dynamic generalized odds-ratio (dGOR) is a powerful measure of association. It is suit-
able for binary, ordinal and continuous outcomes related to SMART studies. Simple odds-ratio
(OR) is widely used in clinical and behavioral sciences because it is easy to interpret. We
suspect that the use of dGOR to compare two DTRs can make SMART design more pop-
ular among practitioners. A freely available online tool (https://sites.google.com/
site/palashghoshstat/sample-size-calculator) using R statistical software is
provided to make the proposed method accessible to other researchers.
In this work, we have considered a SMART that starts with randomization of two initial treat-
ments (A and B), and there are two available treatment options (e.g., E and F ) at each of the
other randomization nodes. The same is also true for the K-stage SMART discussed in Section
7. The dGOR defined in this article can, in principle, also work in a SMART with more than two
treatment options at any stage.
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The responders from the first-stage of SMART described in Figure 1 are not randomized;
instead they continue with the same treatment as in the previous stage. This type of SMARTs
is called “restricted” SMART (Nahum-Shani et al., 2012a). However, there are “unrestricted”
SMARTs where both responders and non-responders are re-randomized potentially to different
treatments (Collins, 2018). We have described dGOR for an “unrestricted” SMART in the Sup-
plementary Material.
We have briefly shown how the notion of dGOR can be used to compare arbitrary regimes,
and thereby can be employed to find an optimal regime within a finite class via policy search.
However, we have not studied any theoretical or computational properties of the policy search
algorithm described. Such a study could be a worthwhile future research endeavour.
12. APPENDIX
12·1. Likelihood for two stage SMART
The ordinal primary outcome Y takes the values in ordered categories 1, · · · , J (higher the
better). Let t1 and t2 be the observed values of T1 and T2. Here we have
Yt1t2 = Y × I{T1 = t1, T2 = t2}
pit1t2,j = P (Yt1t2 = j), (17)
such that
∑J
j=1 pit1t2,j = 1 for any (t1, t2).
The likelihood function for the ith patient who obtained the treatment sequence (T1 =
t1, T2 = t1) or (T1 = t1, T2 = t2) (here, t1 6= t2) with observed outcome denoted as Yi = j; j =
1, · · · , J, can be written as
Li =
τT1i=t1τT2i=t1|T1i=t1γT1i=t1
J−1∏
j=1
pi
I{Yi=j}
t1t1,j
(
1−
J−1∑
j=1
pit1t1,j
)1−J−1∑
j=1
I{Yi=j}

I{T1i=t1,T2i=t1}
×
τT1i=t1τT2i=t2|T1i=t1(1− γT1i=t1)
J−1∏
j=1
pi
I{Yi=j}
t1t2,j
(
1−
J−1∑
j=1
pit1t2,j
)1−J−1∑
j=1
I{Yi=j}

I{T1i=t1,T2i=t2}
,(18)
where γT1i=t1 is the response rate after obtaining treatment T1i = t1 at the first stage; I{·} is
an indicator function; I{T1i = t1, T2i = t1} = 1 denotes a responder and I{T1i = t1, T2i = t2}
denotes a non-responder; τT1i=t1 is the randomization probability at the first stage, which can be
taken as 0.5 under equal randomization at that stage, and τT2i=t2|T1i=t1 denotes the same at the
second stage. Note that, τT2i=t1|T1i=t1 is 1 (for a responder); considering an equal randomization
at the second stage, τT2i=t2|T1i=t1 = 0.5 for a non-responder. The complete likelihood (Thall
et al., 2002) for all the N patients takes the form
L =
N∏
i=1
Li. (19)
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The maximum likelihood estimates of pit1t2,j and γT1=t1 from (19) can be written as
pˆit1t1,j =
N∑
i=1
I{T1i = t1, T2i = t1}I{Yi = j}
N∑
i=1
I{T1i = t1, T2i = t1}
,
for t1 6= t2, pˆit1t2,j =
N∑
i=1
I{T1i = t1, T2i = t2}I{Yi = j}
N∑
i=1
I{T1i = t1, T2i = t2}
, and,
γˆt1 =
N∑
i=1
I{T1i = t1, T2i = t1}
N∑
i=1
I{T1i = t1}
,
respectively. Note that, the likelihood (19) does not consider any embedded regime structure; it
is completely specified by the observed treatment sequences.
12·2. Asymptotic Distribution of dGOR for distinct-path
Here we derive the asymptotic distribution of ηˆDP
d(3),d(1)
that compares two distinct-path regimes
d(1) and d(3). From (2), we can write
ηDP
d(3),d(1)
=
P (Yd(3) > Yd(1))
P (Yd(3) < Yd(1))
=
ΠNu
ΠDe
.
The ΠNu and ΠDe are the numerator and the denominator of ηDPd(3),d(1) , respectively. Define
pAARAE1−RA ,u and pBBRBE1−RB ,s as the maximum likelihood estimates of piAARAE1−RA ,u and
piBBRBE1−RB ,s from the likelihood (19), respectively. Thus,
√
N(ηˆDP
d(3),d(1)
− ηDP
d(3),d(1)
) =
√
N
[
PNu
PDe
− ΠNu
ΠDe
]
=
√
N · PNuΠDe − PDeΠNu
PDeΠDe
, (20)
where PNu and PDe are the estimated version of ΠNu and ΠDe obtained by replacing
corresponding pi values with estimated p. For example, piAARAE1−RA ,u is replaced by the
pAARAE1−RA ,u. Note that, in this derivation, we treat response rates γA and γB as nuisance pa-
rameters and corresponding MLEs obtained from likelihood (19) can used to plug-in the dGOR
expression. The expression (20) has an asymptotic distribution that is same with the asymptotic
distribution of
1
Π2De
·
√
N · [PNuΠDe − PDeΠNu], (21)
using PDe → ΠDe in probability (Goodman & Kruskal, 1963, 1972). Now, we need to find out
the asymptotic distribution of
√
N · [PNuΠDe − PDeΠNu].
Using delta method, the above is asymptotically normal with mean zero and the asymptotic
variance can be obtained as below. Note that, PNu and PDe both are function of pab, a =
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AA,AE,AF,BB,BE,BF ; b = 1, · · · , J . Thus,
∂PNu
∂pab
=
∂
∂pab
∑
RA,RB∈{0,1}
∑
s>u
{
γRAA γ
RB
B (1− γA)1−RA(1− γB)1−RB
×pAARAE1−RA ,upBBRBE1−RB ,s
}
=

0 if a = AF or BF∑
b>u [(1− γA)(1− γB)pAE,u + γA(1− γB)pAA,u] if a = BE∑
b>u [(1− γA)γBpAE,u + γAγBpAA,u] if a = BB∑
s>b [(1− γA)(1− γB)pBE,s + (1− γA)γBpBB,s] if a = AE∑
s>b [γA(1− γB)pBE,s + γAγBpBB,s] if a = AA
= I(a = AA)
∑
s>b
γA [(1− γB)pBE,s + γBpBB,s]
+I(a = AE)
∑
s>b
(1− γA) [(1− γB)pBE,s + γBpBB,s]
+I(a = BB)
∑
b>u
γB [(1− γA)pAE,u + γApAA,u]
+I(a = BE)
∑
b>u
(1− γB) [(1− γA)pAE,u + γApAA,u] ,
where I is an indicator function. Similarly,
∂PDe
∂pab
= I(a = AA)
∑
s<b
γA [(1− γB)pBE,s + γBpBB,s]
+I(a = AE)
∑
s<b
(1− γA) [(1− γB)pBE,s + γBpBB,s]
+I(a = BB)
∑
b<u
γB [(1− γA)pAE,u + γApAA,u]
+I(a = BE)
∑
b<u
(1− γB) [(1− γA)pAE,u + γApAA,u] .
Denote
P
′
ab(Nu) =
∂PNu
∂pab
∣∣∣∣
pab=piab
and
P
′
ab(De) =
∂PDe
∂pab
∣∣∣∣
pab=piab
.
Hence, derivation of PNuΠDe − PDeΠNu w.r.t pab and evaluated at piab is ΠDeP ′ab(Nu)−
ΠNuP
′
ab(De). So, the asymptotic variance of
√
N · [PNuΠDe − PDeΠNu] is same as the asymp-
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totic variance of ∑
a
∑
b
[ΠDeP
′
ab(Nu)−ΠNuP
′
ab(De)]
√
N · (pab − piab), (22)
(Goodman & Kruskal, 1963). Thus, the corresponding variance is∑
a
∑
b
∑
a′
∑
b′
[ΠDeP
′
ab(Nu)−ΠNuP
′
ab(De)][ΠDeP
′
a′b′(Nu)−ΠNuP
′
a′b′(De)]
× 1
ωa
δaa′ [δbb′piab − piabpia′b′ ], (23)
where 1ωa δaa′ [δbb′piab − piabpia′b′ ] is the variance of
√
N · (pab − piab), δkk′ = 1 if k = k′, 0 oth-
erwise and ωa = Na·/N , where Na· is the number of sample from ath population.
In (23), four terms that involve δbb′ are:∑
a
∑
b
1
ωa
Π2De(P
′
ab(Nu))
2piab = Π
2
DeΠNuNu,
where ΠNuNu
=
∑
a
∑
b
1
ωa
(∑
s>b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b>u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)2
piab;(24)
(25)
−
∑
a
∑
b
1
ωa
ΠNuΠDe(P
′
ab(Nu))(P
′
ab(De))piab = −ΠNuΠDeΠNuDe, (two of this),
where ΠNuDe =∑
a
∑
b
1
ωa
(∑
s>b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b>u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)
×(∑
s<b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b<u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)
piab;(26)
and, ∑
a
∑
b
1
ωa
Π2Nu(P
′
ab(De))
2piab = Π
2
NuΠDeDe,
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where ΠDeDe
=
∑
a
∑
b
1
ωa
(∑
s<b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b<u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)2
piab,(27)
(28)
Adding the above four terms we have,
= Π2DeΠNuNu − 2ΠNuΠDeΠNuDe + Π2NuΠDeDe
= Π2De
[
ΠNuNu − 2ΠNu
ΠDe
ΠNuDe +
Π2Nu
Π2De
ΠDeDe
]
= Π2De
[
ΠNuNu − 2ηΠNuDe + η2ΠDeDe
]
= Π2De
∑
a
∑
b
1
ωa
piab ×[(∑
s>b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b>u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)
− ηDP
d(3),d(1)
(∑
s<b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b<u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)]2
. (29)
In (23), the part that do not involve δbb′ is:∑
a
∑
b
∑
a′
∑
b′
[ΠDeP
′
ab(Nu)−ΠNuP
′
ab(De)][ΠDeP
′
a′b′(N)−ΠNuP
′
a′b′(D)]
× 1
ωa
δaa′ [−piabpia′b′ ]. (30)
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The above is non-zero if a = a′. So we can rewrite the above as
−
∑
a
∑
b
∑
b′
[ΠDeP
′
ab(Nu)−ΠNuP
′
ab(De)][ΠDeP
′
a′b′(N)−ΠNuP
′
a′b′(D)] ·
1
ωa
piabpia′b′
= −
∑
a
1
ωa
{∑
b
[ΠDeP
′
ab(Nu)−ΠNuP
′
ab(De)]piab
}{∑
b′
[ΠDeP
′
ab′(N)−ΠNuP
′
ab′(D)]piab′
}
= −
∑
a
1
ωa
{∑
b
[ΠDeP
′
ab(Nu)−ΠNuP
′
ab(De)]piab
}2
= −Π2De
∑
a
1
ωa
{∑
b
[P
′
ab(Nu)− ηDPd(3),d(1)P
′
ab(De)]piab
}2
= −Π2De
[
1
ωAA
(γ2A×{∑
b
piAA,b
{∑
s>b
((1− γB)piBE,s + γBpiBB,s)− ηDPd(3),d(1)
∑
s<b
((1− γB)piBE,s + γBpiBB,s)
}}2
+
1
ωAE
(1− γA)2×{∑
b
piAE,b
{∑
s>b
((1− γB)piBE,s + γBpiBB,s)− ηDPd(3),d(1)
∑
s<b
((1− γB)piBE,s + γBpiBB,s)
}}2
+
1
ωBB
γ2B×{∑
b
piBB,b
{∑
b>u
((1− γA)piAE,u + γApiAA,u)− ηDPd(3),d(1)
∑
b<u
((1− γA)piAE,u + γApiAA,u)
}}2
+
1
ωBE
(1− γB)2×{∑
b
piBE,b
{∑
b>u
((1− γA)piAE,u + γApiAA,u)− ηDPd(3),d(1)
∑
b<u
((1− γA)piAE,u + γApiAA,u)
}}2
= −Π2De
∑
a
1
ωa
×[∑
b
piab
{(∑
s>b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b>u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)
− ηDP
d(3),d(1)
(∑
s<b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b<u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)}]2
. (31)
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Hence the asymptotic variance of
√
N · [PNuΠDe − PDeΠNu] is obtained by adding (29) and
(31).
Finally, using (20), (21), (29) and (31), we have
√
N(ηˆDP
d(3),d(1)
− ηDP
d(3),d(1)
)→ Normal(0, σ2
d(3),d(1)
), where (32)
σ2
d(3),d(1)
=
1
Π2De
∑
a
1
ωa
{∑
b
piab×[(∑
s>b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b>u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)
− ηDP
d(3),d(1)
(∑
s<b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b<u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)]2
−
[∑
b
piab
{(∑
s>b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b>u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)
− ηDP
d(3),d(1)
(∑
s<b
[(1− γB)piBE,s + γBpiBB,s] [γAI(a = AA) + (1− γA)I(a = AE)]
+
∑
b<u
[(1− γA)piAE,u + γApiAA,u] [γBI(a = BB) + (1− γB)I(a = BE)]
)}]2 . (33)
12·3. Asymptotic Distribution of dGOR for shared-path
The expression of the asymptotic variance of
√
N(ηˆSP
d(2),d(1)
− ηSP
d(2),d(1)
) is same as in (33) with
the replacement of d(3) by d(2) and γB by γA. However, the derivation is different from Section
12·2 due to shared component of two shared-path regimes under consideration. The derivation is
shown in Supplementary Material.
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12·4. The asymptotic variance of log(ηˆDP (K)g,g′ )
The asymptotic variance of log(ηˆDP (K)g,g′ ) can be calculated in the same way as in Section 12·2.
The asymptotic variance of log(ηˆDP (K)g,g′ ) is given by N
−1σ2g,g′(K), where
σ2g,g′(K)
=
1
Π2De
∑
a
1
ωa
∑
b
piab ×
[(∑
s>b
Vs +
∑
b>u
Vj
)
− ηDP
d(3),d(1)
(∑
s<b
Vs +
∑
b<u
Vj
)]2
−
[∑
b
piab
((∑
s>b
Vs +
∑
b>u
Vj
)
− ηDP
d(3),d(1)
(∑
s<b
Vs +
∑
b<u
Vj
))]2 ,(34)
where ΠDe is the denominator of η
DP (K)
g,g′ ,
Vs = I(a = 0g
′(K))× (1− γAK−1)(1− γAK−2) · · · (1− γA1)
× [(1− γBK−1)(1− γBK−2) · · · (1− γB1)piB1B2···BK ,s
+
K∑
k=2
γBk−1(1− γBk−2) · · · (1− γB1)piB1B2···Bk−1,s
]
+
[
K∑
k′=2
I(a = 1g′(k′))× γAk′−1(1− γAk′−2) · · · (1− γA1)
]
× [(1− γBK−1)(1− γBK−2) · · · (1− γB1)piB1B2···BK ,s
+
K∑
k=2
γBk−1(1− γBk−2) · · · (1− γB1)piB1B2···Bk−1,s
]
,
and
Vj = I(a = 0g(K))× (1− γBK−1)(1− γBK−2) · · · (1− γB1)
× [(1− γAK−1)(1− γAK−2) · · · (1− γA1)piA1A2···AK ,u
+
K∑
k′=2
γAk′−1(1− γAk′−2) · · · (1− γA1)piA1A2···Ak−1,u
]
+
[
K∑
k=2
I(a = 1g(k))× γBk−1(1− γBk−2) · · · (1− γB1)
]
× [(1− γAK−1)(1− γAK−2) · · · (1− γA1)piA1A2···AK ,u
+
K∑
k′=2
γAk′−1(1− γAk′−2) · · · (1− γA1)piA1A2···Ak−1,u
]
.
Note that, for K = 2, g = 3 and g′ = 1, σ2g,g′(K) in (34) boils down to σ
2
d(3),d(1)
in (33).
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13. SUPPLEMENTARY MATERIAL
The supplementary material includes discussion on “unrestricted” SMART with simulation,
asymptotic distribution of dGOR for comparison of two shared-path regimes, additional analysis
of STAR*D data with four ordinal outcome categories.
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